Your browser doesn't support javascript.
loading
A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy.
Hanaoka, Kaori; Kawato, Yuka; Kubo, Kaori; Nakanishi, Tomonori; Maeda, Masashi; Nakamura, Koji; Hirose, Jun; Noto, Takahisa; Fukahori, Hidehiko; Fujikawa, Akihiko; Miyoshi, Sosuke; Takakura, Shoji; Morokata, Tatsuaki; Higashi, Yasuyuki.
Afiliação
  • Hanaoka K; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: kaori.hanaoka@astellas.com.
  • Kawato Y; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: yuka.kawato@astellas.com.
  • Kubo K; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: kaori.kubo@astellas.com.
  • Nakanishi T; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: tnakanishi@cc.miyazaki-u.ac.jp.
  • Maeda M; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: masashi.maeda@astellas.com.
  • Nakamura K; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: koji.nakamura@astellas.com.
  • Hirose J; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: jun.hirose@astellas.com.
  • Noto T; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: takahisa.noto@santen.co.jp.
  • Fukahori H; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: hidehiko.fukahori@astellas.com.
  • Fujikawa A; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: akihiko.fujikawa@astellas.com.
  • Miyoshi S; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: sosuke.miyoshi@astellas.com.
  • Takakura S; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: shoji.takakura@astellas.com.
  • Morokata T; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: tatsuaki.morokata@astellas.com.
  • Higashi Y; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. Electronic address: yasuyuki.higashi@astellas.com.
Transpl Immunol ; 38: 19-26, 2016 09.
Article em En | MEDLINE | ID: mdl-27545900
ABSTRACT

BACKGROUND:

The Fischer-to-Lewis (LEW) rat model of kidney transplantation is a widely accepted and well-characterized model of chronic rejection. In contrast to transplantation in a clinical setting, however, the absence of treatment with immunosuppressants and only minor mismatch of major histocompatibility complexes (MHCs) are critical discrepancies. Here, we established a rat model of chronic rejection using fully MHC-mismatched strains in which kidney disease progresses even under immunosuppressive therapy.

METHODS:

LEW (RT1(l)) rats were used as donors and Brown Norway (BN, RT1(n)) rats as recipients. Intramuscular administration of 0.1mg/kg of tacrolimus was initiated on the day of transplantation. Post-transplantation, this dose was maintained until Day 9, suspended until Day 28 and then resumed from Day 29. Renal function, histopathology, and levels of donor-specific antibody (DSA) and several biomarkers of renal injury were assessed.

RESULTS:

On Day 91 post-transplantation, recipients received tacrolimus treatment with short-term suspension exhibited reduced renal function and changes in histology. Those were characteristics of chronic rejection including glomerulosclerosis, interstitial fibrosis, and tubular atrophy in human transplantation recipients. Urinary protein excretion increased in a linear fashion, and elevated levels of several biomarkers of renal injury and DSA were observed even under administration of an immunosuppressant.

CONCLUSIONS:

We established an allograft rejection model with impaired renal function and typical histopathological changes of chronic rejection in fully MHC-mismatched rats by controlling administration of an immunosuppressant. These findings suggest that this model more accurately reflects transplantation in a clinical setting than existing models and enables the evaluation of therapeutic agents.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Tacrolimo / Rejeição de Enxerto / Imunossupressores / Rim Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Transpl Immunol Assunto da revista: ALERGIA E IMUNOLOGIA / TRANSPLANTE Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Tacrolimo / Rejeição de Enxerto / Imunossupressores / Rim Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Transpl Immunol Assunto da revista: ALERGIA E IMUNOLOGIA / TRANSPLANTE Ano de publicação: 2016 Tipo de documento: Article